Sirtuin1 protects against systemic sclerosis–related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes

American Journal of Respiratory Cell and Molecular Biology

Volumn 58, Issue 1, 2018, Pages 28-39

  Chu, Haiyan ^a   Jiang, Shuai ^a   Liu, Qingmei ^a,b   Ma, Yanyun ^c   Zhu, Xiaoxia ^b,d   Liang, Minrui ^b,d   Shi, Xiangguang ^a   Ding, Weifeng ^a,e   Zhou, Xiaodong ^f   Zou, Hejian ^b,d   Qian, Feng ^c   Shaul, Philip W ^g   Jin, Li ^a   Wang, Jiucun ^a,d  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c School of Life Sciences   (China)

^d FUDAN UNIVERSITY   (China)

^e NANTONG UNIVERSITY   (China)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Inflammation; NF kB pathway; Pulmonary fibrosis; Systemic sclerosis; Transforming growth factor b mammalian target of rapamycin pathway

Indexed keywords

BLEOMYCIN; COLLAGEN; DECAPENTAPLEGIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE; RAPAMYCIN; RESVERATROL; SIRTUIN 1; TRANSFORMING GROWTH FACTOR BETA; SIRT1 PROTEIN, HUMAN; SIRT1 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; FETUS LUNG; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG FIBROBLAST; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MOUSE; MTOR SIGNALING; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROPHYLAXIS; PROTEIN ACETYLATION; PROTEIN DEPLETION; SYSTEMIC SCLEROSIS; ANIMAL; CELL LINE; COMPLICATION; ENZYME ACTIVATION; ENZYMOLOGY; MALE; METABOLISM;

ANIMALS; CELL LINE; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MICE; NF-KAPPA B; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SIRTUIN 1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85039861203     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2016-0192OC     Document Type: Article

References (53)

1. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol 2013;32:617–621.
2. Homer RJ, Herzog EL. Recent advances in pulmonary fibrosis: implications for scleroderma. Curr Opin Rheumatol 2010;22: 683–689.
3. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985;28:759–767.
4. Wu T, Chu H, Tu W, Song M, Chen D, Yuan J, et al. Dissection of the mechanism of traditional Chinese medical prescription–Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis. BMC Complement Altern Med 2014;14:224.
5. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157–179.
6. Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014;66:1967–1978.
7. Veraldi KL, Hsu E, Feghali-Bostwick CA. Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Curr Rheumatol Rep 2010;12:19–25.
8. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest 2012;122:2756–2762.
9. Toonkel RL, Hare JM, Matthay MA, Glassberg MK. Mesenchymal stem cells and idiopathic pulmonary fibrosis: potential for clinical testing. Am J Respir Crit Care Med 2013;188:133–140.
10. Vaillant P, Menard O, Vignaud JM, Martinet N, Martinet Y. The role of cytokines in human lung fibrosis. Monaldi Arch Chest Dis 1996;51: 145–152.
11. Di Paola R, Talero E, Galuppo M, Mazzon E, Bramanti P, Motilva V, et al. Adrenomedullin in inflammatory process associated with experimental pulmonary fibrosis. Respir Res 2011;12:41.
12. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339–1350.
13. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004;73:417–435.
14. Chen B, Zang W, Wang J, Huang Y, He Y, Yan L, et al. The chemical biology of sirtuins. Chem Soc Rev 2015;44:5246–5264.
15. Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol 2015;309:H1375–H1389.
16. Sharples AP, Hughes DC, Deane CS, Saini A, Selman C, Stewart CE. Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake. Aging Cell 2015;14: 511–523.
17. Ming M, Zhao B, Shea CR, Shah P, Qiang L, White SR, et al. Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 2015;135: 936–945.e4.
18. Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X, et al. Activation of Sirt1 by resveratrol inhibits TNF-a induced inflammation in fibroblasts. PLoS One 2011;6:e27081.
19. Moon MH, Jeong JK, Lee YJ, Seol JW, Jackson CJ, Park SY. SIRT1, a class III histone deacetylase, regulates TNF-a–induced inflammation in human chondrocytes. Osteoarthritis Cartilage 2013;21:470–480.
20. Gillum MP, Kotas ME, Erion DM, Kursawe R, Chatterjee P, Nead KT, et al. SirT1 regulates adipose tissue inflammation. Diabetes 2011;60: 3235–3245.
21. Wei J, Ghosh AK, Chu H, Fang F, Hinchcliff ME, Wang J, et al. The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor b signaling. Arthritis Rheumatol 2015;67:1323–1334.
22. Zerr P, Palumbo-Zerr K, Huang J, Tomcik M, Sumova B, Distler O, et al. Sirt1 regulates canonical TGF-b signalling to control fibroblast activation and tissue fibrosis. Ann Rheum Dis 2016;75:226–233.
23. Huang XZ, Wen D, Zhang M, Xie Q, Ma L, Guan Y, et al. Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-b/Smad3 pathway. J Cell Biochem 2014;115:996–1005.
24. Cappetta D, Esposito G, Piegari E, Russo R, Ciuffreda LP, Rivellino A, et al. SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy. Int J Cardiol 2016;205:99–110.
25. Wu Y, Liu X, Zhou Q, Huang C, Meng X, Xu F, et al. Silent information regulator 1 (SIRT1) ameliorates liver fibrosis via promoting activated stellate cell apoptosis and reversion. Toxicol Appl Pharmacol 2015; 289:163–176.
26. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–590.
27. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000;106:1341–1350.
28. Liu Q, Chu H, Ma Y, Wu T, Qian F, Ren X, et al. Salvianolic acid B attenuates experimental pulmonary fibrosis through inhibition of the TGF-b signaling pathway.Sci Rep 2016;6:27610.
29. Zhang M, Li W, Yu L, Wu S. The suppressive effect of resveratrol on HIF-1a and VEGF expression after warm ischemia and reperfusion in rat liver. PLoS One 2014;9:e109589.
30. Ponnusamy M, Zhou X, Yan Y, Tang J, Tolbert E, Zhao TC, et al. Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 2014;350:243–256.
31. Liang J, Tian S, Han J, Xiong P. Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction. Ren Fail 2014;36:285–291.
32. Hong SW, Jung KH, Zheng HM, Lee HS, Suh JK, Park IS, et al. The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Res 2010;33:601–609.
33. Ito K. Impact of post-translational modifications of proteins on the inflammatory process. Biochem Soc Trans 2007;35:281–283.
34. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006;173:769–776.
35. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40: 362–382.
36. Mitra A, Luna JI, Marusina AI, Merleev A, Kundu-Raychaudhuri S, Fiorentino D, et al. Dual mTOR inhibition is required to prevent TGF-b–mediated fibrosis: implications for scleroderma. J Invest Dermatol 2015;135:2873–2876.
37. Gui YS, Wang L, Tian X, Li X, Ma A, Zhou W, et al. mTOR overactivation and compromised autophagy in the pathogenesis of pulmonary fibrosis. PLoS One 2015;10:e0138625.
38. Park JS, Park HJ, Park YS, Lee SM, Yim JJ, Yoo CG, et al. Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients. BMC Pulm Med 2014;14:168.
39. Fried L, Kirsner RS, Bhandarkar S, Arbiser JL. Efficacy of rapamycin in scleroderma: a case study. Lymphat Res Biol 2008; 6:217–219.
40. Tamaki Z, Asano Y, Kubo M, Ihn H, Tada Y, Sugaya M, et al. Effects of the immunosuppressant rapamycin on the expression of human a2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts. J Dermatol Sci 2014;74: 251–259.
41. Zhou XL, Xu JJ, Ni YH, Chen XC, Zhang HX, Zhang XM, et al. SIRT1 activator (SRT1720) improves the follicle reserve and prolongs the ovarian lifespan of diet-induced obesity in female mice via activating SIRT1 and suppressing mTOR signaling. J Ovarian Res 2014;7:97.
42. Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009;48:iii40–iii44.
43. Xie J, Zhang X, Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res 2013;67:60–67.
44. Yang SR, Wright J, Bauter M, Seweryniak K, Kode A, Rahman I. Sirtuin regulates cigarette smoke–induced proinflammatory mediator release via RelA/p65 NF-kB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol 2007;292:L567–L576.
45. Tino AB, Chitcholtan K, Sykes PH, Garrill A. Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-kB protein. J Ovarian Res 2016; 9:84.
46. Martín AR, Villegas I, Sánchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006;147:873–885.
47. Holmes-McNary M, Baldwin AS Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkB kinase. Cancer Res 2000;60:3477–3483.
48. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012;15: 675–690.
49. Kessoku T, Imajo K, Honda Y, Kato T, Ogawa Y, Tomeno W, et al. Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. Sci Rep 2016;6:22251.
50. Kulkarni YM, Dutta S, Iyer AK, Venkatadri R, Kaushik V, Ramesh V, et al. A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis. Proteomics 2016;16:33–46.
51. Poolman TM, Ng LL, Farmer PB, Manson MM. Inhibition of the respiratory burst by resveratrol in human monocytes: correlation with inhibition of PI3K signaling. Free Radic Biol Med 2005;39:118–132.
52. Inoue Y, King TE Jr, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Criti Care Med 2002;166: 765–773.
53. Uchiyama T, Toda K, Takahashi S. Resveratrol inhibits angiogenic response of cultured endothelial f-2 cells to vascular endothelial growth factor, but not to basic fibroblast growth factor. Biol Pharm Bull 2010;33:1095–1100.